Close Menu

NEW YORK (GenomeWeb) – Exact Sciences — whose Cologuard colorectal cancer diagnostic test has been steadily gaining market share — is focusing on expanding the test's label to a new patient group, creating a new and improved version of the diagnostic, and developing new liquid biopsy tests for other types of cancer.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.